AU2021243725A1 - 5-amino-8-(4-pyridyl)-(1,2,4)triazolo(4,3-c)pyrimidin-3-one compounds for use against cancer - Google Patents
5-amino-8-(4-pyridyl)-(1,2,4)triazolo(4,3-c)pyrimidin-3-one compounds for use against cancer Download PDFInfo
- Publication number
- AU2021243725A1 AU2021243725A1 AU2021243725A AU2021243725A AU2021243725A1 AU 2021243725 A1 AU2021243725 A1 AU 2021243725A1 AU 2021243725 A AU2021243725 A AU 2021243725A AU 2021243725 A AU2021243725 A AU 2021243725A AU 2021243725 A1 AU2021243725 A1 AU 2021243725A1
- Authority
- AU
- Australia
- Prior art keywords
- pyridyl
- amino
- triazolo
- pyrimidin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994970P | 2020-03-26 | 2020-03-26 | |
| US62/994,970 | 2020-03-26 | ||
| PCT/EP2021/057807 WO2021191379A1 (en) | 2020-03-26 | 2021-03-25 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021243725A1 true AU2021243725A1 (en) | 2022-10-27 |
Family
ID=75339741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021243725A Pending AU2021243725A1 (en) | 2020-03-26 | 2021-03-25 | 5-amino-8-(4-pyridyl)-(1,2,4)triazolo(4,3-c)pyrimidin-3-one compounds for use against cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12528815B2 (https=) |
| EP (1) | EP4126873A1 (https=) |
| JP (1) | JP7774573B2 (https=) |
| KR (1) | KR20230051118A (https=) |
| CN (1) | CN115867280B (https=) |
| AU (1) | AU2021243725A1 (https=) |
| CA (1) | CA3177056A1 (https=) |
| WO (1) | WO2021191379A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| ATE457988T1 (de) | 2006-06-26 | 2010-03-15 | Schering Corp | A2a-adenosin-rezeptor-antagonisten |
| JP2011513417A (ja) * | 2008-03-04 | 2011-04-28 | シェーリング コーポレイション | アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物 |
| AU2011306358B2 (en) | 2010-09-24 | 2014-08-14 | Impetis Biosciences Ltd. | Fused tricyclic compounds as adenosine receptor antagonist |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| AU2018233367B2 (en) | 2017-03-16 | 2021-08-12 | Jiangsu Hengrui Medicine Co., Ltd. | Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof |
-
2021
- 2021-03-25 CA CA3177056A patent/CA3177056A1/en active Pending
- 2021-03-25 EP EP21715862.5A patent/EP4126873A1/en active Pending
- 2021-03-25 KR KR1020227037223A patent/KR20230051118A/ko active Pending
- 2021-03-25 CN CN202180038082.7A patent/CN115867280B/zh active Active
- 2021-03-25 US US17/914,196 patent/US12528815B2/en active Active
- 2021-03-25 JP JP2022558345A patent/JP7774573B2/ja active Active
- 2021-03-25 WO PCT/EP2021/057807 patent/WO2021191379A1/en not_active Ceased
- 2021-03-25 AU AU2021243725A patent/AU2021243725A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115867280B (zh) | 2025-05-27 |
| CA3177056A1 (en) | 2021-09-30 |
| US12528815B2 (en) | 2026-01-20 |
| JP7774573B2 (ja) | 2025-11-21 |
| JP2023519361A (ja) | 2023-05-10 |
| EP4126873A1 (en) | 2023-02-08 |
| KR20230051118A (ko) | 2023-04-17 |
| CN115867280A (zh) | 2023-03-28 |
| WO2021191379A1 (en) | 2021-09-30 |
| US20230146483A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114901664B (zh) | 吡啶酮化合物及应用 | |
| CA2927252C (en) | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors | |
| TW201127385A (en) | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | |
| WO2015025026A1 (en) | Alkynyl alcohols and methods of use | |
| EP4327877A2 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| KR20140139023A (ko) | 암을 치료하기 위한 6-(4-(1-아미노-3-하이드록시사이클로부틸)페닐)-5-페닐(퓨로, 싸이에노 또는 피롤로)[2,3-d]피리미딘-4-온 유도체 | |
| JP7675094B2 (ja) | トリアゾロン化合物 | |
| CN115867280B (zh) | 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物 | |
| EP4455129A1 (en) | Dna polymerase theta inhibitor and use thereof | |
| JP2017100951A (ja) | オキサゾリジノン及びオキサジナノン誘導体 | |
| WO2021156439A1 (en) | Triazole compounds as adenosine receptor antagonists | |
| CA3113732C (en) | Aromatic heterocyclic compound with kinase inhibitory activity | |
| CN115867550B (zh) | 三唑酮化合物 | |
| WO2021191376A1 (en) | Triazolone compounds | |
| HK40088927B (en) | Triazolone compounds | |
| HK40088927A (en) | Triazolone compounds | |
| WO2025207620A1 (en) | Akt1 modulators | |
| WO2024179948A1 (en) | Indazole compounds as pkmyt1 kinase inhibitors | |
| TWI690528B (zh) | 稠環雙環吡啶基衍生物 | |
| TW202504586A (zh) | 治療發炎性疾病之方法 |